52 results about "Glycated Hb" patented technology

The invention relates to the technical field of medical informatics, in particular to an AI-based intelligent early warning system for hyperuricemia male reproductive metabolism abnormality. The system comprises a memory and a processor, and the processor executes a computer program stored in the memory to realize the following steps: acquiring uric acid data, waistline data, glycosylated hemoglobin data and reproductive index data of a target male; combining the uric acid fluctuation abnormality degree, the multi-dimensional blood glucose abnormality expression degree and the movement rule expression degree of each stage to obtain the reproduction metabolism abnormality degree; according to the relative relationship between the reproductive index data and the corresponding standard range, obtaining the abnormal performance degree of the reproductive index; integrating the reproductive metabolism abnormality degree and the reproductive index abnormality expression degree to obtain a multi-dimensional feature linkage reproductive metabolism expression comprehensive evaluation degree of the target male; and according to the comprehensive evaluation degree of the multi-dimensional feature linkage reproductive metabolism performance, whether early warning is carried out is judged. According to the invention, the accuracy and credibility of intelligent early warning of the risk of abnormal male reproductive metabolism of hyperuricemia are improved.

An electronic device comprises a housing configured to contact a user's skin, an optical transmitter array, an optical receiver, a memory element and a processing element. The optical transmitter array outputs a plurality of optical signals that pass through the user's skin, each of the plurality of optical signals having one of three wavelengths. The optical receiver receives the optical signals and generates corresponding photoplethysmogram (PPG) signals. The memory element stores absorption constants for deoxyhemoglobin blood content, oxyhemoglobin blood content and glycated hemoglobin blood content, each absorption constant associated with one of the first wavelength, the second wavelength or the third wavelength. The processing element determines a glycated hemoglobin blood level for the user based on a ratio of a determined glycated hemoglobin blood content to a sum of determined deoxyhemoglobin blood content, a determined oxyhemoglobin blood content and a determined glycated hemoglobin blood content.

The application belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of a styrene microsphere for glycosylated hemoglobin detection. The styrene microsphere is prepared through a dispersion polymerization method, a seed polymerization method and a preparation step of organic high molecular particles. The microsphere prepared in the application has moderate particle size and concentrated distribution, good uniformity of the microsphere particle size, a hydroxyl covering on the surface of the microsphere to form a hydrophilic layer, and can effectively reduce the matrix effect, so as to achieve accurate analysis of glycosylated hemoglobin HbA1c. The result is accurate, stable and small in error in the detection, and the application can be applied to quantitative detection of diabetes.

The invention discloses a split-type glycosylated hemoglobin analysis device, and relates to the field, the split-type glycosylated hemoglobin analysis device comprises a host and a split-type isolation cover, the top of the host is provided with a modular analysis part, and the upper edge of the modular analysis part is provided with four modular assembly ports; a sample tube, a first analysis module, a second analysis module and a cleaning module are detachably assembled in the four modular assembly ports respectively, the split type isolation hood is detachably assembled above the main machine, and a control part and a sampling device are mounted at the positions, above the modular analysis part, in the split type isolation hood; the control part can control the sampling device to respectively move to a first position, a second position, a third position and a fourth position. A split modular mounting structure is adopted, and the sample tube, the first analysis module, the second analysis module and the cleaning module in the device can be taken out from modular assembly ports in the modular analysis part, so that the modules are more convenient to replace, clean and disinfect.

The invention relates to a glycosylated hemoglobin HbA1c freeze-drying detection reagent and a preparation method and application thereof.The preparation method comprises the steps that surface aminated polystyrene microspheres are prepared through an emulsion polymerization method, then double bonds are introduced through Schiff base reaction and methylacrolein reaction, and the glycosylated hemoglobin HbA1c freeze-drying detection reagent is obtained. Then preparing anionic polystyrene microspheres with hydrophilic chains through free radical polymerization, and preparing freeze-dried powder of the HbA1c detection reagent R1 by adopting the anionic polystyrene microspheres; the preparation method comprises the following steps: preparing a hydrophilic cross-linking agent 2, 5-bis (2, 4-dihydroxy-6-formylphenoxy) terephthalaldehyde, then carrying out a Schiff base reaction on the hydrophilic cross-linking agent 2, 5-bis (2, 4-dihydroxy-6-formylphenoxy) terephthalaldehyde and HbA1c mAb to prepare an HbA1c oligomer, and preparing the HbA1c detection reagent R2 freeze-dried powder by using the HbA1c oligomer. The glycosylated hemoglobin HbA1c freeze-drying detection reagent prepared by the invention has the advantages of high antigen binding efficiency, excellent detection sensitivity, sufficient retention of antibody activity and strong detection specificity.

The invention discloses an ACS patient prognosis prediction method, which is characterized in that ACS patient prognosis is predicted through a trained and verified ACS patient prognosis prediction model, and prediction factors of the prediction model comprise patient age, heart rate, heart function grading, urea nitrogen and glycosylated hemoglobin. The predictive factors are screened by adopting multi-factor Cox regression analysis. The prediction model comprises a column chart model, and a column chart scale comprises a scale score range of 0-100, a patient age range of 25-95, a heart rate range of 40-140, a heart function grading range of I-IV, a urea nitrogen range of 0-35, a glycosylated hemoglobin range of 4-15, a total score range of 0-240 and a survival rate range of 0.99-0.01.

The invention relates to the technical field of non-invasive glycosylated hemoglobin detection, and discloses non-invasive glycosylated hemoglobin detection test paper and method.The non-invasive glycosylated hemoglobin detection test paper comprises a sampling layer, a combination cushion layer is bonded to the lower surface of the sampling layer, and a nitrocellulose membrane layer is bonded to the side face, away from the sampling layer, of the combination cushion layer; a water absorption layer is adhered to one side surface, far away from the combined cushion layer, of the nitrocellulose membrane layer; a PVC bottom plate is adhered to one side surface, far away from the nitrocellulose membrane layer, of the water absorption layer; through cooperation of the structures, the pain feeling during sampling can be reduced, and the tissue fluid collecting efficiency is improved.

The invention provides a biomarker composition and an application thereof. The biomarker composition comprises the following proteins: MMP12, UMOD, HbA1c, FGF9, NINJ1 and PRSS8. According to the biomarker composition provided by the invention, through combination of matrix metalloproteinase 12, uromodulin, glycosylated hemoglobin, FGF9, NINJ1 and serine protease 8, the problem of lack of a specific marker for aortic wall structure damage in the prior art is solved.

The application relates to a biochemical analyzer and a detection method for detecting glycated hemoglobin. The hemoglobin concentration and the glycated hemoglobin concentration of a to-be-detected whole blood sample are obtained, and the content proportion of the glycated hemoglobin is calculated according to the hemoglobin concentration and the glycated hemoglobin concentration. The hemoglobin concentration is obtained by the following steps: obtaining a first absorbance of a to-be-detected sample liquid at a hemoglobin measurement wavelength, wherein the to-be-detected sample liquid is prepared by mixing a to-be-detected whole blood sample, a hemolytic agent and a hemoglobin detection reagent; obtaining at least two second absorbances of the to-be-detected sample liquid at at least two different correction wavelengths, wherein the correction wavelengths are designed so that the absorbance of a lipid interferent at the correction wavelength is greater than the absorbance of hemoglobin at the correction wavelength; correcting the first absorbance according to the second absorbance; and determining the hemoglobin concentration according to the corrected first absorbance. The application can improve the accuracy of hemoglobin detection.

A method of providing personalized treatment for a diabetes patient including a remote device which is configured to receive a first data indicative of an analyte level of a subject during a first time period, retrieve a first glycated hemoglobin level for the subject associated with the first time period, calculate a first personal apparent glycation ratio for the first time period using the received first data and the retrieved first glycated hemoglobin level, compare the calculated first personal apparent glycation ratio to a representative apparent glycation ratio, generate a recommendation based on the comparison, and display a graphical interface comprising the calculated first personal apparent glycation ratio, the representative apparent glycation ratio, and the comparison.

A non-invasive biosignal measurement device based on skin effect removal, includes: a signal measurement instrument measuring a PPG signal of a measurement subject in contact with the skin on one side of a specific body part of the measurement subject; a signal reception unit receiving the PPG signal from the signal measurement instrument; and a ratio value calculation unit removing noise due to a skin effect from the PPG signal, and then calculating ratio values at different wavelengths for measuring a biosignal including blood sugar and glycated hemoglobin of the measurement subject. The signal measurement instrument includes a first sensor module including an optical barrier and a second sensor module for removing the skin effect.

The utility model discloses a high-precision glycosylated hemoglobin detection kit, which relates to the technical field of glycosylated hemoglobin detection kits, and comprises a kit body, a detection reagent bottle, a hemolytic reagent bottle and a sampling dropper are placed in the kit body, a dropper cover is clamped at an opening at one end of the hemolytic reagent bottle, and the sampling dropper is clamped at the other end of the hemolytic reagent bottle. One side, close to the hemolytic reagent bottle, of the dropper cover is fixedly connected with a sealing conical plug; the hemolytic reagent bottle is connected with the dropper cover in a clamped mode, one-hand operation can be achieved, the hemolytic reagent bottle can be opened and closed, work efficiency is improved, the sealing conical plug can be tightly attached to a bottle opening of the hemolytic reagent bottle, hemolytic reagent leakage is prevented, the risk that a reagent is polluted is reduced, and when a blood sample and a detection reagent are mixed, the hemolytic reagent bottle is not damaged. The mixing dropper can accurately control the output quantity of a treated blood sample, and meanwhile, the sample is prevented from splashing out due to too fast flowing, so that errors possibly generated in an intermediate link are reduced.

In at least one embodiment, a hemoglobin measuring device may include a plurality of sensors, a display configured to present information, and a computing device in communication with the sensors and display and having a processor and a memory storing instructions executable by the processor. The instructions may include instructions to receive, from the sensors, measurements of one or more forms of glycated hemoglobin in a blood samples, determine a total fetal hemoglobin value in the blood sample by performing a peak area summation of all forms of fetal hemoglobin, subtract the total fetal hemoglobin value from 100 to derive a total adult hemoglobin value, determine a glycated fetal hemoglobin value, compare the glycated fetal hemoglobin value to a reference range to obtain a comparison, determine a baseline glucose control value based on the comparison, and output the baseline glucose control value and the comparison to a display for medical evaluation.

The present application relates to the technical field of glycated hemoglobin detection, and particularly relates to a glycated hemoglobin chromatographic detection method for pregnancy risk assessment, comprising the following steps: obtaining serum ferritin concentration, glycated hemoglobin concentration and C-reactive protein concentration of pregnant women; analyzing reference value weight of each pregnant woman according to distribution of serum ferritin concentration and C-reactive protein concentration of each pregnant woman and body mass index of each pregnant woman, and then obtaining data correction coefficient; obtaining serum ferritin reference value according to serum ferritin concentration, C-reactive protein concentration and glycated hemoglobin concentration of pregnant women; adjusting glycated hemoglobin concentration of a target pregnant woman according to data correction coefficient, serum ferritin reference value and serum ferritin concentration of the target pregnant woman, and then obtaining glycated hemoglobin detection result of the target pregnant woman. The present application can eliminate interference caused by iron deficiency or anemia, and make glycated hemoglobin detection result more accurate.

The application discloses a mesenchymal stem cell preparation expressing FOXO3 and FGF21 and application thereof, relates to biological medicine, and a parent plasmid carrying a therapeutic gene of the mesenchymal stem cell expressing FOXO3 and FGF21 has a nucleotide sequence as shown in SEQ ID No: 01; the application provides a mesenchymal stem cell preparation capable of simultaneously expressing FOXO3 and FGF21, which can effectively improve insulin glucose tolerance, effectively reduce the content of glycosylated hemoglobin, and has the potential to treat human type 2 diabetes.

The invention discloses a latex enhanced immunoturbidimetry detection reagent for glycosylated hemoglobin and a use method of the latex enhanced immunoturbidimetry detection reagent, and relates to the technical field of medical examination. The latex enhanced immunoturbidimetry detection reagent for glycosylated hemoglobin comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises first nano microspheres; and the reagent R2 comprises a second nano microsphere coated with a monoclonal antibody of HbA1c. According to the reagent R2, the nano microspheres are coated with the monoclonal antibody of HbA1c, the stability risk caused by the fact that balance needs to be established for immunoreaction of multiple antibodies and antigens is avoided through the monoclonal antibody, the problem that a glycosylated hemoglobin immunoturbidimetry detection reagent is insufficient in stability can be solved, the nano microspheres are arranged on the reagent R2, and therefore the stability of the glycosylated hemoglobin immunoturbidimetry detection reagent is improved, and the stability of the glycosylated hemoglobin immunoturbidimetry detection reagent is improved. By utilizing the characteristic that the volume of an antigen-antibody conjugate can be increased after the nano-microspheres are combined with the HbA1c monoclonal antibody, the turbidimetric degree of latex is effectively amplified, and the detection sensitivity can be improved.

The invention relates to the technical field of glycosylated hemoglobin detection, in particular to a glycosylated hemoglobin detection method based on magnetic bead affinity adsorption, which comprises the following steps: A, sample pretreatment; b, total hemoglobin detection: detecting the absorbance H1 of the sample after hemolysis; c, carrying out affinity reaction; d, magnetic separation: starting an electromagnet tightly attached to the wall of the cuvette, and adsorbing the functionalized magnetic beads to the wall of the cuvette by adopting the electromagnet; e, non-glycosylated hemoglobin detection: detecting the absorbance H2 of the supernatant under the same optical path; and F, result calculation: calculating according to a formula HbA1c% = (H1-H2) / H1 * 100% to obtain a detection value of glycosylated hemoglobin. The glycosylated hemoglobin detection method disclosed by the invention is simple and convenient to operate, low in cost and very easy to realize automation. Compared with other high performance liquid chromatography methods for detecting glycosylated hemoglobin, the cost of a detection instrument is reduced by 70%, and the cost of a single test reagent is reduced by 30%.

The invention provides a model for predicting dementia based on gaits and glycosylated hemoglobin, which is characterized in that according to a model construction method, an insole consisting of a plurality of pressure sensor diaphragms and a shoe with a distance sensor at the heel part are adopted for acquiring pressure distribution data and ground clearance data; the combined model of glycosylated hemoglobin prediction on the basis of judgment of walking and turning postures is formed and used for judging the development stage of dementia, a complex system for shooting and collecting images for judgment is avoided, and meanwhile misjudgment of pure diabetes mellitus can be avoided in combination with glycosylated hemoglobin prediction.

The application discloses a series of glycated hemoglobin specific elimination systems, a preparation method and application thereof. The system is an AIE fluorescent positioning group as a skeleton anchor point, and orderly polymerization of the system with a disulfide bond, a diselenide bond, a ditelluride bond and other stimulus response groups is realized through a Schiff base reaction, so that a series of novel oxidative stress response covalent organic framework materials are constructed, and the excellent self-assembly performance of a hydrazine bond PEG group is utilized to identify the glycated protein capture potential. The series of glycated hemoglobin specific elimination systems have a myocardial targeting property, a long residence time, a significant glycated hemoglobin self-capture system, realize stable and long-acting elimination of a disease course marker glycated hemoglobin and specific targeting regulation of myocarditis inflammatory microenvironment macrophages, provide a new idea and a new tool for targeted treatment of a complex pathogenesis of diabetic cardiomyopathy, and have good research significance and excellent clinical transformation value.

The application provides a glycated hemoglobin dissociation reagent and application thereof, and belongs to the technical field of biological detection. The dissociation reagent comprises 10-50 mM Tris buffer, 0.2-0.5 M ammonium chloride, 0.5%-1.0% (v / v) triton X-100, 0.2 wt%-1.0 wt% BSA and 0.02-0.2 M sodium chloride. When the dissociation reagent is used to dissociate a whole blood sample, the hemoglobin can be dissociated by mixing the dissociation reagent with the whole blood sample for 20-60 s, and a clear and transparent solution is obtained. The dissociation reagent can be used to prepare a kit for dissociating or / and detecting glycated hemoglobin. The glycated hemoglobin obtained by using the dissociation reagent can be directly used for fluorescence immunoassay, the interference of the color of hemoglobin itself on immunochromatographic detection is avoided, and the sensitivity is high and the repeatability is good.

A glycated hemoglobin percentage detection method includes: obtaining optical response information of a blood under test; performing a normalization and correction process based on the optical response information of the blood under test of a first wavelength to obtain normalized optical response information of the blood under test; selecting normalized optical response information of a second wavelength and normalized optical response information of a third wavelength from the normalized optical response information of the blood under test for analysis to determine a glycated hemoglobin percentage in the blood under test.

The application relates to a sample analyzer and a sample analysis method. The sample analyzer comprises: a sample preparation device configured to prepare a pretreatment test solution by using a blood sample and a pretreatment reagent, prepare an interferent detection test solution by using the pretreatment test solution and a first detection reagent, and prepare a to-be-tested sample solution by using the pretreatment test solution or the interferent detection test solution and a second detection reagent; a first detection device configured to detect the interferent detection test solution to obtain interferent information; a second detection device configured to detect the to-be-tested sample solution to obtain a hemoglobin detection result and / or a glycated hemoglobin detection result of the blood sample; and a controller configured to output prompt information when the interferent information indicates that there is an interferent in the blood sample which interferes with the hemoglobin detection and / or the glycated hemoglobin detection. The embodiments of the application can detect the interferent and output corresponding interferent prompt information when the hemoglobin and / or the glycated hemoglobin is detected.

Provided is a method for measuring glycated hemoglobin in a sample containing hemoglobin and plasma, the method including reacting glycated hemoglobin in a sample containing hemoglobin and plasma, a proteolytic enzyme, and a fructosyl peptide oxidase to generate hydrogen peroxide, and measuring the generated hydrogen peroxide, wherein the reaction is performed in the presence of ferrocyanide and a ferrocene derivative.

This invention relates to the field of medical informatics technology, specifically to an AI-based intelligent early warning system for male reproductive metabolic abnormalities in patients with hyperuricemia. The system includes a memory and a processor. The processor executes a computer program stored in the memory to perform the following steps: acquiring uric acid data, waist circumference data, glycated hemoglobin data, and reproductive indicator data of the target male; combining the abnormality of uric acid fluctuations at each stage, the abnormality of multidimensional blood glucose levels, and the abnormality of exercise patterns to obtain the degree of reproductive metabolic abnormality; obtaining the degree of abnormality of reproductive indicators based on the relative relationship between the reproductive indicator data and the corresponding standard ranges; comprehensively assessing the multidimensional features linked to the reproductive metabolic performance of the target male based on the degree of reproductive metabolic abnormality and the degree of abnormality of reproductive indicators; and determining whether to issue an early warning based on the comprehensive assessment of the multidimensional features linked to the reproductive metabolic performance. This invention improves the accuracy and reliability of intelligent early warning systems for the risk of male reproductive metabolic abnormalities in patients with hyperuricemia.

To provide a device and a method for easily hemolyzing / diluting puncture blood even is the device is an A1c measuring device using the HPLC method.SOLUTION: Glycosylated hemoglobin (A1c%) is measured by a chip set that is formed of a conical or pyramid-shaped chip made of resin that can suck up puncture blood by a capillary phenomenon, a container that can store the chip, and a lid body that can seal the container, and can collect the puncture blood and hemolyze and dilute the blood, the chip set capable of collecting puncture blood and hemolyzing and diluting the blood, wherein the container has an inner diameter larger than the maximum outer diameter of the chip by 0.5 to 5 mm, and the container has therein a flange that has a columnar shape having a height allowing storage of the chip and is at a position 5 to 15 mm from a top face of the container, and a method for collecting puncture blood and hemolyzing / diluting the blood by using the chip.SELECTED DRAWING: Figure 7

The invention relates to an automatic check method of glycosylated hemoglobin, a sample analysis device and a sample analysis system.The method comprises the steps that basic information of a detected person is obtained, and a detection value related to blood sugar and a detection value related to red blood cells of the detected person are obtained; according to the basic information of the detected person, the detection value related to the blood sugar and the detection value related to the red blood cells, calculating an estimated value of glycosylated hemoglobin of the detected person; and automatically checking the detection value of the glycosylated hemoglobin of the detected person according to the estimated value of the glycosylated hemoglobin of the detected person. The invention provides an automatic auditing scheme for glycosylated hemoglobin, the workload of auditing personnel can be reduced, and the auditing personnel can concentrate on auditing a small part of detection values of glycosylated hemoglobin which does not pass automatic auditing and is suspected to have problems.

The utility model discloses an anti-clogging sampling device of a glycosylated hemoglobin instrument, and relates to the technical field of glycosylated hemoglobin analysis, the anti-clogging sampling device comprises a protein instrument shell, the top of the inner side wall of the protein instrument shell is fixedly provided with a support frame through a bolt, and the edge of one side of the support frame is movably connected with a moving assembly through a rotating shaft; a fixed table is fixedly mounted on the surface of one side of the moving assembly, an extension surface is arranged in the middle of the surface of one side of the fixed table, a sample injection pipe is connected to the extension surface of one side of the fixed table in a penetrating manner, and a hollow pipe body is movably connected to the inner arc surface of the sample injection pipe in a sleeving manner; according to the utility model, the fixed block slides along with the synchronous belt, so that the stability of transverse movement is ensured, and then the electric push rod is driven to enable the extension end of one side of the electric push rod to drive the fixed table to move downwards, so that the sample injection tube can stably move in the longitudinal direction, and the sample injection tube is aligned to a test tube body through the transverse and longitudinal stable movement; liquid sample injection can be accurately carried out, and the possibility of blockage is reduced.

The invention relates to the technical field of glycosylated hemoglobin detection, in particular to a glycosylated hemoglobin chromatographic detection method for pregnancy risk assessment, which comprises the following steps: acquiring serum ferritin concentration, glycosylated hemoglobin concentration and C-reactive protein concentration of a pregnant woman; according to the distribution condition of the serum ferritin concentration and the C-reactive protein concentration of each pregnant woman and the body mass index of each pregnant woman, analyzing the reference value weight of each pregnant woman, and further obtaining a data correction coefficient; obtaining a serum ferritin reference value according to the serum ferritin concentration, the C-reactive protein concentration and the glycosylated hemoglobin concentration of the pregnant woman; and adjusting the glycosylated hemoglobin concentration of the target pregnant woman according to the data correction coefficient, the serum ferritin reference value and the serum ferritin concentration of the target pregnant woman to obtain a glycosylated hemoglobin detection result of the target pregnant woman. According to the invention, interference caused by iron deficiency or anemia can be eliminated, so that the detection result of glycosylated hemoglobin is more accurate.

Disclosed is a method for measuring glycated hemoglobin in a sample, the method including: a step for mixing a sample containing glycated hemoglobin with a first reagent to obtain a reaction solution containing a fructosyl peptide; a step for adding a second reagent to the reaction solution, thereby causing a leuco-type chromogen to develop a color; a step for calculating the change in absorbance of the mixed solution of the reaction solution and the second reagent due to the color development of the leuco-type chromogen, where the change in absorbance is the difference between a first absorbance immediately after the addition of the second reagent and a second absorbance after a prescribed time has elapsed from the measurement of the first absorbance; and a step for determining the concentration of glycated hemoglobin in the sample on the basis of the change in absorbance.